omniture

Tianyin Pharmaceutical Co., Inc. to Participate in Susquehanna Financial Group, LLLP Second Annual Beijing Management Summit in Beijing on September 10, 2008

2008-08-22 00:28 1060

CHENGDU, China, Aug. 22 /Xinhua-PRNewswire/ -- Tianyin Pharmaceutical, Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and supplier of modernized traditional Chinese medicine (“TCM”) based in Chengdu, China, today announced that the Company will participate in Susquehanna Financial Group, LLLP’s Second Annual Beijing Management Summit on Wednesday, September 10, 2008. The Conference will be held on September 10-12, 2008 at the Grand Hyatt Hotel in Beijing.

The management will participate in meetings with analysts and investors throughout the day. Dr. Guoqing Jiang, Chairman and CEO, will present on the Company’s behalf, to discuss the Company’s current product portfolio, development pipeline, research and development platform, recent financial highlights and its long term growth strategy.

Participation in the Summit is by invitation only and the Company is honored to be part of such a prestigious event. For more information on the conference contact your Susquehanna Financial Group representative or visit http://www.sig.com .

About Susquehanna Financial Group, LLLP

Susquehanna International Group, LLP (SIG) is comprised of affiliated entities, including Susquehanna Financial Group, LLLP (SFG). Susquehanna Financial Group, LLLP operates as an institutional sale, research, and market making firm. SFG is a member of FINRA. The company offers solutions in listed, NASDAQ, exchange traded funds, options, program trading, and American depositary receipts. It is an institutional brokerage affiliate of Susquehanna International Group, LLP (SIG), and publishes and distributes SIG’s research. The company is based in Bala Cynwyd, Pennsylvania.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 32 modernized TCMs and 4 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 49 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,187 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007. For more information about Tianyin Pharmaceuticals, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.

Source: Tianyin Pharmaceutical, Co., Inc.
Related Stocks:
NYSE:TPI
collection